Progression-Free Survival Improvements Favour Pembolizumab Plus Chemotherapy Over Chemotherapy in Patients with Advanced TNBC Enrolled in Asia
Patients enrolled from Asia demonstrated consistent findings with those in the overall population of the KEYNOTE-355 study